Israeli medical company Gamida Cell will move forward with testing its second pipeline product – NiCord, for treatment of blood cancer and other blood-related conditions. The trials are expected to show results within 6 months. This announcement comes two weeks after the company’s announcement of its contact with pharmaceutical giant Pfizer, with intention of commercializing Gamida Cell’s flagship product – StemEX.
Related posts
Researchers Use Nano-technology To Help Body Fight Cancer
August 11, 2022
Why NBA Superstar Is Investing In Israeli Healthcare Startup
August 11, 2022
Women Who Fled Ukraine War To Study In Israel For Free
August 10, 2022
Smart Cart Startup Shopic Announces $35M Funding
August 10, 2022
Facebook comments